## Model Type III Sum of Squares [General Statistics]

Hello obi,

» » Type III SS for a factor A is essentially the SS for A

»

» OK, so that implies that Type III for factor B and C becomes SS(B|A∩C) and SS(C|A∩B) respectively?

This would be my best guess yes, but please do not rely on anything I say in relation to anything. Or suffer the consequences

» How about Type I SS for factors A, B and C (in that order)? Would it be SS(A), SS(B|A) and SS(C|A∩B) respectively?

As above.

» OK that's true. This could possibly be part of the reason why Type I and type III SS are not the same even in a balanced BE design.

Please explain. When there is balance then the type I and type III SS should be the same in these BE trials, shouldn't they? Your Venn diagram should in my expectation have no overlapping circles.

» » Type III SS for a factor A is essentially the SS for A

*given B and C in the model.*I guess you might refer to that as SS(A|B∩C),»

» OK, so that implies that Type III for factor B and C becomes SS(B|A∩C) and SS(C|A∩B) respectively?

This would be my best guess yes, but please do not rely on anything I say in relation to anything. Or suffer the consequences

» How about Type I SS for factors A, B and C (in that order)? Would it be SS(A), SS(B|A) and SS(C|A∩B) respectively?

As above.

» OK that's true. This could possibly be part of the reason why Type I and type III SS are not the same even in a balanced BE design.

Please explain. When there is balance then the type I and type III SS should be the same in these BE trials, shouldn't they? Your Venn diagram should in my expectation have no overlapping circles.

—

Best regards,

ElMaestro

"(...) targeted cancer therapies will benefit fewer than 2 percent of the cancer patients they’re aimed at. That reality is often lost on consumers, who are being fed a steady diet of winning anecdotes about miracle cures." New York Times (ed.), June 9, 2018.

` if (3) 4 `

x=c("Foo", "Bar")

b=data.frame(x)

typeof(b[,1]) ##aha, integer?

b[,1]+1 ##then let me add 1

Best regards,

ElMaestro

"(...) targeted cancer therapies will benefit fewer than 2 percent of the cancer patients they’re aimed at. That reality is often lost on consumers, who are being fed a steady diet of winning anecdotes about miracle cures." New York Times (ed.), June 9, 2018.

### Complete thread:

- Model Type III Sum of Squares - Obinoscopy, 2018-12-16 07:58 [General Statistics]
- Model Type III Sum of Squares - ElMaestro, 2018-12-16 19:49
- Model Type III Sum of Squares - Obinoscopy, 2018-12-18 19:10
- Model Type III Sum of Squares - ElMaestro, 2018-12-18 21:32
- Model Type III Sum of Squares - Obinoscopy, 2018-12-20 20:42
- Model Type III Sum of Squares - ElMaestro, 2018-12-21 03:49
- Model Type III Sum of Squares - Obinoscopy, 2018-12-23 16:44
- Model Type III Sum of Squares - ElMaestro, 2018-12-23 18:21
- Model Type III Sum of Squares - Obinoscopy, 2018-12-25 16:56

- Model Type III Sum of Squares - ElMaestro, 2018-12-23 18:21

- Model Type III Sum of Squares - Obinoscopy, 2018-12-23 16:44

- Model Type III Sum of Squares - ElMaestro, 2018-12-21 03:49

- Model Type III Sum of Squares - Obinoscopy, 2018-12-20 20:42

- Model Type III Sum of Squares - ElMaestro, 2018-12-18 21:32

- Model Type III Sum of Squares - Obinoscopy, 2018-12-18 19:10

- Model Type III Sum of Squares - ElMaestro, 2018-12-16 19:49